Opioid Receptor Antagonist

Opioid Receptor Antagonists (71):

Cat. No.	Product Name	Effect	Purity

HY-17417

Naloxone hydrochloride	Antagonist	99.96%
Naloxone hydrochloride is an antagonist of Opioid receptor. Naloxone hydrochloride alleviates opioid-overdose-induced respiratory depression. Naloxone hydrochloride may cause pulmonary edema and cardiac arrhythmias.

HY-10487

JDTic dihydrochloride	Antagonist	98.03%
JDTic (dihydrochloride) is a potent antagonist of kappa-opioid receptors (KOR), blocking the κ-agonist U50, 488-induced antinociception.

HY-17417A

Naloxone	Antagonist	99.71%
Naloxone is an antagonist of Opioid receptor. Naloxone alleviates opioid-overdose-induced respiratory depression. Naloxone may cause pulmonary edema and cardiac arrhythmias.

HY-101302

Naltriben mesylate	Antagonist	99.65%
Naltriben mesylate is a potent δ2-opioid receptor antagonist and a TRPM7 activator. Naltriben mesylate shows K_i values of 0.013 nM, 19 nM and 152 nM for δ, μ and κ receptors, respectively. Naltriben mesylate enhances glioblastoma cell migration and invasion. Naltriben mesylate can be used in research into neurological diseases and cancer.

HY-76711

Naltrexone	Antagonist	99.94%
Naltrexone is an antagonist of Opioid receptor. Naltrexone inhibits cell proliferation in vivo. Naltrexone reduces tumor growth by interfering with cell signalling and modifying the immune system.

HY-117040

nor-Binaltorphimine	Antagonist	98.70%
nor-Binaltorphimine is a selective antagonist of kappa-opioid receptor. nor-Binaltorphimine has a long-lasting effect in vivo.

HY-A0118A

Naloxegol oxalate	Antagonist	99.91%
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation.

HY-13243

Alvimopan	Antagonist	98.66%
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC₅₀ of 1.7 nM. Alvimopan has selectivity for μ-opioid receptor (K_i=0.47 nM) over κ- and δ-opioid receptors (K_is=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus.

HY-137279

Naloxone methiodide	Antagonist	99.7%
Naloxone methiodide is a peripherally restricted, nonselective, and competitive opioid receptor antagonist. Naloxone methiodide does not penetrate the blood-brain barrier.

HY-101376

(+)-N-Allylnormetazocine hydrochloride	Antagonist	99.0%
(+)-N-Allylnormetazocine ((+)-SKF 10047) hydrochloride is a benzomorphan opioid with psychotomi metic effects. (+)-N-Allylnormetazocine hydrochloride is an opioid receptor antagonist with K_i values of 300 nM and 27 μM for σ1 and σ2 opioid receptors, respectively. (+)-N-Allylnormetazocine hydrochloride can be used for the research of neurological disease.

HY-123689

Samidorphan	Antagonist	99.04%
Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioid receptors. Samidorphan acts as an antagonist at μ‐opioid receptors and acts as a partial agonist at k-opioid and δ‐opioid receptors. Samidorphan primarily acts as an opioid receptor antagonist in vivo. Samidorphan can improve the behavior of depressed animals.

HY-15708

LY2795050	Antagonist	98.12%
LY2795050 is a short-acting selective κ(kappa)-opioid receptor (KOR) antagonist. LY2795050 has high affinity for the KOR with K_i value of 0.72 nM. LY2795050 can be used for the research of central nervous system dysfunction.

HY-114452A

LY2940094 tartrate	Antagonist	99.66%
LY2940094 (BTRX-246040) tartrate is a potent, brain penetrant, selective and orally available N/OFQ peptide (NOP) receptor antagonist with high affinity (K_i=0.105 nM) and antagonist potency (K_b=0.166 nM). LY2940094 tartrate reduces Ethanol self-administration and Ethanol seeking in animal models.

HY-16765A

Axelopran sulfate	Antagonist	99.14%
Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.

HY-107749

ML 190	Antagonist	99.60%
ML 190 is a selective κ opioid receptor (KOR) antagonist with an IC₅₀ of 120 nM and an EC₅₀ of 129 nM, respectively.

HY-108229S

6β-Naltrexol-d₃	Antagonist	99.72%
6β-Naltrexol-d₃ (6β-Hydroxynaltrexone-d₃) is deuterium labeled 6β-Naltrexol. 6β-Naltrexol (6β-Hydroxynaltrexone), the primary metabolite of Naltrexone, is a peripherally selective opioid antagonist. 6β-Naltrexol selectively inhibits gastrointestinal opioid effects in human subjects and inhibits Morphine-induced slowing of gastrointestinal transit.

HY-118416

BMS-986124	Antagonist	99.00%
BMS-986124 is a μ-opioid receptor silent allosteric modulator (μ-SAMs). BMS-986124 antagonizes positive allosteric modulator effect of BMS-986122 (µ-OR PAM).

HY-19627

Naldemedine	Antagonist
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC₅₀=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CL^pro encoded by SARS-CoV2 genome.

HY-A0118

Naloxegol	Antagonist
Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation.

HY-107750

Cyprodime	Antagonist
Cyprodime is a selective μ opioid receptor (MOR) antagonist with K_is of 5.4, 244.6, and 2187 nM for μ, δ, and κ, respectively.

Name
Email *

	Sorry, but the email address you supplied was invalid.